Clinical Trial Update: Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 clinical trial evaluating ABT-101 in advanced solid tumors and non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABT-101 (ABT-101)

Snippet

Sponsor: Anbogen Therapeutics, Inc. | Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING